Literature DB >> 27597268

Antibacterial action of lipid nanocapsules containing fatty acids or monoglycerides as co-surfactants.

Anita Umerska1, Viviane Cassisa2, Nada Matougui3, Marie-Laure Joly-Guillou2, Matthieu Eveillard2, Patrick Saulnier3.   

Abstract

Lipid nanocapsules (LNCs) are a new generation of biomimetic nanocarriers obtained via a phase inversion temperature method and have an oily core of medium-chain triglycerides that is surrounded by a shelf containing a lipophilic surfactant (lecithin) and a hydrophilic surfactant macrogol 15-hydroxystearate. The aim of the present study was to produce LNCs with antibacterial activity by replacing lecithin with other lipophilic surface active compounds, namely medium-chain fatty acids and their 1-monoglycerides, which are known to have antimicrobial properties. Fatty acids and monoglycerides were found to affect the properties of LNCs, such as particle size and zeta potential. Incorporation of a co-surfactant decreased significantly particle size (p⩽0.0039). Furthermore, incorporation of either lecithin or fatty acids with at least 10 carbon atoms yielded LNCs with the zeta potential significantly more negative than that of LNCs composed solely of triglycerides and macrogol 15 hydroxystearate (p⩽0.0310). Moreover, they were capable of decreasing the phase inversion temperature. The activity of the LCNs against Gram-positive S. aureus, including a methicillin-resistant strain, increased with increases in the length of the hydrocarbon tail. Monoglyceride-LNCs were found to be more active than the corresponding fatty acids. The opposite behaviour was observed for Gram-negative bacteria, whereby only caproic acid- and caprylic acid-LNCs were found to be active against these organisms. The monoglyceride-LNCs were bactericidal, and they killed in a time-dependent manner. Fatty acid-LNCs killed in a concentration-dependent manner. A haemolysis assay was performed to obtain preliminary information on the safety of the tested LNCs. In the case of fatty acid-LNCs, the concentrations at which bacterial growth was inhibited were similar to the haemolytic concentrations. However, monoglyceride-LNCs showed antibacterial action at concentrations much lower than those at which haemolysis was observed. In conclusion, monoglyceride-LNCs are promising candidates as carriers for the encapsulation of antibacterial agents, particularly against S. aureus.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibacterial; Antibiotics; Fatty acids; Lauric acid; Lipid; Lipid nanocapsules; Monocaprin; Monoglycerides; Monolaurin; Nanoparticles; Natural products

Mesh:

Substances:

Year:  2016        PMID: 27597268     DOI: 10.1016/j.ejpb.2016.09.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  10 in total

Review 1.  Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.

Authors:  Chelsea R Thorn; Nicky Thomas; Ben J Boyd; Clive A Prestidge
Journal:  Drug Deliv Transl Res       Date:  2021-03-05       Impact factor: 4.617

Review 2.  Antimicrobial Peptides: An Emerging Category of Therapeutic Agents.

Authors:  Margit Mahlapuu; Joakim Håkansson; Lovisa Ringstad; Camilla Björn
Journal:  Front Cell Infect Microbiol       Date:  2016-12-27       Impact factor: 5.293

3.  Synergistic interactions between antimicrobial peptides derived from plectasin and lipid nanocapsules containing monolaurin as a cosurfactant against Staphylococcus aureus.

Authors:  Anita Umerska; Viviane Cassisa; Guillaume Bastiat; Nada Matougui; Hassan Nehme; Florence Manero; Matthieu Eveillard; Patrick Saulnier
Journal:  Int J Nanomedicine       Date:  2017-08-08

4.  Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity.

Authors:  Hassan Nehme; Patrick Saulnier; Alyaa A Ramadan; Viviane Cassisa; Catherine Guillet; Matthieu Eveillard; Anita Umerska
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

5.  Surface active properties of lipid nanocapsules.

Authors:  Celia R A Mouzouvi; Anita Umerska; André K Bigot; Patrick Saulnier
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

6.  Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats.

Authors:  José Hureaux; Franck Lacoeuille; Frédéric Lagarce; Marie-Christine Rousselet; Aurélien Contini; Patrick Saulnier; Jean-Pierre Benoit; Thierry Urban
Journal:  Int J Nanomedicine       Date:  2017-11-08

7.  Characterization of the in vitro, ex vivo, and in vivo Efficacy of the Antimicrobial Peptide DPK-060 Used for Topical Treatment.

Authors:  Joakim Håkansson; Lovisa Ringstad; Anita Umerska; Jenny Johansson; Therese Andersson; Lukas Boge; René T Rozenbaum; Prashant K Sharma; Petter Tollbäck; Camilla Björn; Patrick Saulnier; Margit Mahlapuu
Journal:  Front Cell Infect Microbiol       Date:  2019-05-28       Impact factor: 5.293

8.  Fluoroquinolone Amorphous Polymeric Salts and Dispersions for Veterinary Uses.

Authors:  Hanah Mesallati; Anita Umerska; Lidia Tajber
Journal:  Pharmaceutics       Date:  2019-06-09       Impact factor: 6.321

9.  Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani.

Authors:  Prakash Kumar; Saptarshi Mandal; Surendra Rajit Prasad; Anu Mohan; Radhika Chaurasia; Ashish Shrivastava; Pallaprolu Nikhil; Dande Aishwarya; P Ramalingam; Rahul Gajbhiye; Shriya Singh; Arunava Dasgupta; Mukesh Chourasia; V Ravichandiran; Prolay Das; Debabrata Mandal
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

10.  Synergistic Effect of Combinations Containing EDTA and the Antimicrobial Peptide AA230, an Arenicin-3 Derivative, on Gram-Negative Bacteria.

Authors:  Anita Umerska; Magnus Strandh; Viviane Cassisa; Nada Matougui; Matthieu Eveillard; Patrick Saulnier
Journal:  Biomolecules       Date:  2018-10-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.